BACKGROUND: D-dimers have a high Q2 negative predictive value for excluding venous thromboembolism outside of pregnancy but the use in pregnancy remains controversial. A higher cut-off value has been proposed in pregnancy due to a continuous increase across gestation. Fibrin monomer complexes have been considered as an alternative diagnostic tool for exclusion of venous thromboembolism in pregnancy due to their different behavior. OBJECTIVE: We sought to establish normal values of fibrin monomer complexes and D-dimer as a diagnostic tool for the exclusion of venous thromboembolism in pregnancy and examine the effect of maternal and obstetric factors on these markers. STUDY DESIGN: Plasma D-dimer and fibrin monomer complexes were measured by quantitative immunoturbidimetry in 2870 women with singleton pregnancies attending their routine first-trimester hospital visit in a prospective screening study for adverse obstetric outcome. Multiple regression analysis was used to determine maternal characteristics and obstetric factors affecting the plasma concentrations and converting these into multiple of the median values after adjusting for significant maternal and obstetric characteristics. RESULTS: Plasma fibrin monomer complexes increased with maternal weight and were lower in women with a history of cocaine abuse and chronic hypertension. D-dimers increased with gestational age and maternal weight and were higher in sickle cell carriers and in women of African and South Asian racial origin compared to Caucasians. CONCLUSION: Fibrin monomer complexes and D-dimers are affected by maternal and obstetric characteristics rather than only gestational age. The utility of these fibrin-linked markers as a tool for exclusion of venous thromboembolism in pregnancy might be improved by adjusting for patient-specific characteristics.
Introduction
Pregnancy is a hypercoagulable state exemplifying Virchow triad of altered coagulation, stasis, and vascular damage. 1 Venous thromboembolism (VTE) is one of the leading causes of maternal death in developed countries with about 1-2 deaths per 100,000 maternities or 9% of all maternal deaths in the United States. 2, 3 The incidence of VTE in pregnancy is 1-2 per 1000, 5-fold higher than in nonpregnant women. 4 The antenatal risk for VTE is highest in the first and third trimester 5 and in the United Kingdom the majority of antenatal deaths occurred in the first trimester. 6 Outside of pregnancy, diagnostic pathways for deep vein thrombosis (DVT) and pulmonary embolism are based on a combination of clinical scoring systems, blood tests, and imaging using compression ultrasound, ventilation-perfusion scans, or computed tomography pulmonary angiography. 7 Both ventilationperfusion scans and computed tomography pulmonary angiography are considered safe but concerns remain about fetal radiation and breast radiation exposure, respectively, with these modalities. 8 In pregnancy there are no clinically validated scoring systems and the clinical presentation can be confused with features of a healthy pregnancy. 9 D-dimer (DD) is integral to diagnostic pathways outside of pregnancy and in individuals with low clinical probability has a high negative predictive value for VTE. 10 Another marker of thrombin activation is the fibrin monomer (FM), an intermediate in cross-linked fibrin formation. FM are produced when thrombin proteolyses fibrinogen Q3 into fibrinopeptides A and B and FM. In prothrombotic conditions such as disseminated intravascular coagulation syndrome soluble complexes may be formed when FM join with fibrinogen and fibrin degradation products. 11 DD are produced by lysis of cross-linked fibrin and are therefore downstream from FM in this pathway. However DD levels normally rise in pregnancy and higher cut-off value have been proposed. 12 There is evidence that DD and FM might behave differently in clinical scenarios, possibly reflecting the different stages of thrombin activation and fibrinolysis. For instance, there are small studies showing that changes in FM concentrations in uncomplicated pregnancy seem to be minimal compared to other hemostatic markers and FM are therefore considered an alternative tool for exclusion of VTE in pregnancy. 13, 14 It would be desirable to be able to utilize fibrin-linked markers within pregnancy to help exclude the likelihood of VTE and reduce the requirement for imaging as shown for the use of FM outside pregnancy. 15, 16 Further, it is likely that characteristics of the mother as well as the pregnancy might also affect hemostatic markers. The objectives of this screening study at 11-13 weeks' gestation are to establish a reference range for plasma FM and DD and examine the maternal and pregnancy characteristics that affect the measurements.
Materials and Methods

Study population
The data for the study were derived from prospective screening for adverse obstetric outcomes in women attending their routine hospital visit in the firsttrimester of pregnancy at King's College Hospital, London, from October 2011 through May 2012. This visit, which was held at 11 þ0 -13 þ6 weeks' gestation, included recording of maternal characteristics and medical history, ultrasound examination for measurement of fetal crown-rump length, diagnosis of fetal abnormalities, and measurement of fetal nuchal translucency thickness as part of combined screening for fetal trisomies. 17 Venous blood (4 mL) was obtained from the antecubital vein and collected into tubes containing liquid 0.109 mol/L trisodium citrate (BD Medical Systems, Franklin Lakes, NJ).
Written informed consent was obtained from the women agreeing to participate in the study, which was approved by the ethics committee of the hospital. The pregnancies included in the study were those resulting in live birth or stillbirth of phenotypically normal babies at 24 weeks' gestation. Women on current anticoagulation were excluded.
Patient characteristics
Patient characteristics recorded included maternal age; racial origin (Caucasian, Afro-Caribbean, South Asian, East Asian, and mixed); method of conception (spontaneous or assisted conception requiring the use of ovulation drugs); cigarette smoking during pregnancy; medical history of chronic hypertension, diabetes mellitus, sickle cell trait, and autoimmune disease, including systemic lupus erythematosus or rheumatoid arthritis; family history of thromboembolic events; and obstetric history including parity (parous or nulliparous if no previous pregnancies at 24 weeks' gestation). The maternal weight and height were measured.
Sample analysis
The blood samples were processed within 1 hour after collection. After centrifugation at 2200g for 15 minutes at 20 C the undiluted plasma was analyzed immediately in the STA-Compact coagulation analyzer (Diagnostica Stago, Asnières-sur-Seine, France) by quantitative immunoturbidimetry following the manufacturer's instructions. We used STA-Liatest FM (Diagnostica Stago) and STA-Liatest DD (Diagnostica Stago) assays with respective working ranges of 5-150 mg/mL and 0.22-4.0 mg /mL, and an expected normal threshold in the adult nonpregnant population of <6 mg/mL for FM and <0.5 mg/mL (expressed in FEU) for Q4 DD. The intraassay and interassay coefficients of variation were 5.55% and 5.7% for FM and 8.4% and 10.3% for DD, respectively.
Pregnancy outcome
Data on pregnancy outcome were collected from the hospital maternity records or the general medical practitioners of the women. The birthweight percentile for gestational age at delivery was derived from a reference range for our population. 18 The definition of preeclampsia was that of the International Society for the Study of Hypertension in Pregnancy. 19 Diagnosis of gestational diabetes mellitus was based on a 75-g oral glucose tolerance test performed at 24-28 weeks' gestation. 20 
Statistical analysis
Data for continuous variables are presented as median (interquartile range) and data for categorical variables are presented as n (%). The observed values of serum DD and FM concentrations were log 10 transformed to make their distributions gaussian. Normality was assessed using histograms and probability plots. Univariable regression analysis was used to examine the individual variables contributing significantly to prediction of log 10 -transformed values of DD and FM. Multivariable regression analysis with backward stepwise regression analysis was used to determine the significance of contribution from maternal and pregnancy characteristics. The measured concentration of DD and FM were converted into multiple of the median (MoM) values after adjusting for maternal characteristics that significantly affected log 10 -transformed values in the multiple regression analysis. A statistical software package (SPSS 21; IBM Corp, Armonk, NY) was used for data analyses.
Results
Study population
During the study period we examined 2870 singleton pregnancies with a live fetus at 11-13 weeks, but 256 were excluded: miscarriage or termination for fetal abnormalities and those with major fetal defects (n ¼ 107), anticoagulation therapy (n ¼ 28), or no pregnancy follow-up (n ¼ 121). The characteristics of the study population of 2614 pregnancies are shown in Table 1 ½T1 . In keeping with the South East London population Q5 , 61.7% women were Caucasian, 27.9% Afro-Caribbean, and 10.5% of other ethnic origins. DD was measured in all cases but FM was measured in only 1286 of the cases due to reagent availability.
FM complex
The median and 5th and 95th percentiles of the measured FM concentration were 4.3, 2.16, and 8.84 mg/L, respectively. In 282 (21.9%) of the 1286 pregnancies the values were >6 mg/L. Univariable regression analysis demonstrated that significant contributions to log 10 FM were provided by several maternal and pregnancy ½T2 characteristics ( Table 3   ½T3 ). Multivariable Q6 regression analysis demonstrated that significant contributions to log 10 FM were provided by maternal weight, cocaine use, and medical history of chronic hypertension (Figure 1 111  112  113  114  115  116  117  118  119  120  121  122  123  124  125  126  127  128  129  130  131  132  133  134  135  136  137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162  163  164  165  166   167  168  169  170  171  172  173  174  175  176  177  178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219 220 221
D-dimer
The median and 5th and 95th percentiles of the measured DD concentration were 0.31, 0.11, and 1.16 mg/L, respectively. In 736 (28.2%) of the 2614 pregnancies the values were >0.5 mg/L. Univariable regression analysis demonstrated that significant contributions to log 10 DD were provided by several maternal and pregnancy characteristics ( Table 2 ). Multivariable regression analysis demonstrated that significant contributions to log 10 DD were provided by gestational age, maternal weight, smoking, maternal ethnic origin, and medical history of sickle cell trait ( Figure 1) .
The median and 5th, 10th, 90th, and 95th percentiles, with 95% confidence intervals for DD MoM, were: 0.98 (0.96e1.00), 0.37 (0.34e0.39), 0.47 (0.46e0.49), 2.23 (2.09e2.34), and 2.93 (2.73e3.18), respectively ( Figure 2 ).
Comment
This study has established a reference range for serum FM and DD in singleton pregnancies at 11-13 weeks' gestation and reports the maternal and pregnancy characteristics that affect the measurements. The study also illustrates that the cut-offs of 6 mg/L for FM and 0.5 mg/L for DD used for exclusion of VTE in nonpregnant individuals are not applicable to pregnancy because these values were already exceeded by the end of the first trimester in 22% and 28% of cases, respectively.
Multivariable regression analysis demonstrated that the level of FM increased with maternal weight and was decreased in women with chronic hypertension and those reporting use of cocaine. The level of DD increases with gestational age and maternal weight and is higher in those with sickle cell trait. DD is increased in women of Afro-Caribbean and South Asian racial origin relative to Caucasians, and it is decreased in cigarette smokers. We also examined the association with pregnancy outcomes: levels of DD and FM at 11-13 weeks' gestation were not 223  224  225  226  227  228  229  230  231  232  233  234  235  236  237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278   279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334 significantly altered in pregnancies that subsequently developed preeclampsia, fetal growth restriction, or gestational diabetes mellitus.
Strengths and limitations
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One limitation of the study is that despite the fact that all women were clinically free from signs or symptoms of VTE at the time of testing, we did not exclude the possibility of asymptomatic VTE. This potential complication could TABLE 3 Univariable and multivariable regression analysis to examine factors from maternal and pregnancy characteristics affecting concentration of log 10 559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594 In our study using the STA-Liatest assays (Diagnostica Stago), the median DD at 11-13 weeks' gestation was 0.31 mg/L. Several previous studies in small numbers of cases ranging from 5-350 normal pregnancies at <16 weeks' gestation reported that the median DD varied between 0.1-0.8 mg/L. 12, 13, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] For the STA-Liatest assay (Diagnostica Stago) we found in the literature firsttrimester concentrations of 0.3, 21 0.49, 28 and 0.2 mg/L in a Chinese population 26 ; 0.48 mg/L in women without DVT; and 5.4 mg/L in women with confirmed DVT. 30 None of the previous studies in pregnant women on either FM or DD examined the possible association of levels with maternal demographic characteristics. However, a study in 4364 mainly nonpregnant individuals presenting to a medical emergency department examined the effect of patient characteristics on DD level and reported significant positive associations with several factors including black race, cocaine use, rheumatoid arthritis, SLE, and sickle cell trait. 35 Our finding of increasing levels of both FM and DD with maternal weight might reflect the increased susceptibility of obese women to VTE. 36 Maternal obesity is also histopathologically associated with chronic villitis and fetal thrombosis. 37 Similarly the association of increased levels of DD in women of Afro-Caribbean racial origin is compatible with the increased susceptibility of these women to VTE. 38 It is possible that there might be ethnic differences in the regulation of proteins in the coagulation cascade; a further example is the elevated levels of factor VIII in the black population, both in healthy subjects and those with VTE, relative to those of Caucasian origin. 39 Individuals with sickle cell trait have an association with increased coagulation activity but the mechanism is not well understood. 40 Pregnant women with increased body mass index, sickle cell carriers, and those of African and South Asian origin have elevated DD MoM and smokers have decreased DD MoM. The utility of this finding in improving diagnostic performance of DD has to be evaluated in future studies including pregnant women with confirmed VTE.
Currently, we can only speculate why FM behave differently than DD and are negatively affected by chronic hypertension and cocaine use. A subanalysis of the women with FM concentrations >95th percentile showed that the median DD concentration in this group was 0.44 mg/L and therefore not similarly high. FM were not affected by the analyzed pregnancy complications but lower in women with chronic hypertension and cocaine use, both conditions associated with vasoconstriction, smaller placental size, and placental abruption. 41 Platelet activation through the 5HT pathway independent of thrombin formation is an underlying mechanism linked to both conditions. [42] [43] [44] Decreased FM may also reflect impaired maternal-placental attachment 45 and at term fibrinogen predicts adverse maternal or neonatal outcomes in patients with placental abruption. 46 Several previous studies have reported elevated DD levels in women with established preeclampsia and 1 study showed elevated DD in women with a history of preeclampsia outside of pregnancy [47] [48] [49] ; hypercoagulability and increased fibrin deposition were proposed as an underlying mechanism. Our finding that DD were not significantly altered at 11-13 weeks in women who subsequently develop preeclampsia suggests that such activity may not precede the clinical onset of the disease and is certainly not present from the first trimester.
Conclusion
By contributing to the establishment of a reference range for STA-Liatest FM and DD (Diagnostica Stago) and identifying the maternal characteristics that affect these markers at 11-13 weeks, we open the possibility of using fibrin-linked markers as a diagnostic screening tool for VTE in pregnancy. Further, the traditional approach to thromboprophylaxis in pregnancy is to identify the highrisk group for VTE from maternal characteristics and medical history, including previous VTE, increased maternal age and body mass index, assisted conception, and preeclampsia. 2, 50 An integrated first hospital visit at 11-13 weeks during which data from maternal characteristics and history are combined with findings of biophysical and biochemical tests can already define the patient-specific risk for a wide spectrum of pregnancy complications, including fetuses with aneuploidy, miscarriage and fetal death, preterm delivery, preeclampsia, gestational diabetes, fetal growth restriction, and macrosomia. 17, 51 A similar approach of early pregnancy risk assessment might have the potential to be applied to VTE. Future studies might investigate how risk scoring and prevention of VTE might be improved by this new approach to pregnancy care. n
